Health Canada licenses Light AI’s QuickScan Strep A smartphone software for suspected strep throat assessment

The Canadian authorisation moves Light AI’s AI-enabled throat-image analysis platform from investigational development into its first regulated market, providing healthcare professionals with a software-based tool to support assessment of suspected Group A Streptococcus infection.

Health Canada has issued a medical device licence for Light AI’s QuickScan Strep A, a smartphone-enabled Software as a Medical Device designed to assist healthcare professionals in assessing patients with suspected Group A Streptococcus pharyngitis.

The authorisation represents a material regulatory step for Light AI, whose platform analyses throat images using artificial intelligence without requiring proprietary diagnostic hardware.

Field	Content
Alert Type	Drug Approval
Drug Name	QuickScan Strep A
Indication	Software as a Medical Device intended to assist healthcare professionals in the assessment of patients presenting with symptoms consistent with pharyngitis and suspected Group A Streptococcus (Strep A) infection.
Therapy Area(s)	Infectious diseases; Primary care; Diagnostics
Geography	Canada (Health Canada)
What Happened	Health Canada has issued Light AI a medical device licence for QuickScan Strep A, the company’s AI-enabled Software as a Medical Device for assessment of suspected Group A Streptococcus pharyngitis. The platform is designed to analyse throat images captured using compatible smart devices and provide an AI-supported assessment. The authorisation follows Light AI’s completion of ISO 13485:2016 and Medical Device Single Audit Program certification in June 2026, which supported its planned Canadian regulatory submission. Earlier company disclosures described QuickScan Strep A as investigational and unavailable for commercial diagnostic use, meaning the Health Canada licence represents a change in its Canadian regulatory status. (Stockwatch)
Why It Matters	Strep A and viral pharyngitis can present with overlapping symptoms, while determining whether a bacterial infection is present can influence subsequent testing and treatment decisions. QuickScan’s software-based approach is intended to provide healthcare professionals with an additional assessment tool using compatible smart-device images rather than proprietary diagnostic hardware; the Health Canada licence permits regulated Canadian use within the authorised indication but does not by itself establish reimbursement or widespread clinical adoption.
Supporting Context	Light AI has been pursuing parallel regulatory development in Canada and the US. In June 2026, it initiated a US pivotal clinical trial comparing QuickScan Strep A with throat culture to generate evidence for a planned FDA Class II submission; the FDA programme remains separate from the Canadian authorisation. (Light AI)
Key Takeaway	Health Canada’s licence gives Light AI its first regulated pathway for QuickScan Strep A as an AI-supported smartphone tool for assessing suspected Strep A infection.
What to Watch	Canadian commercial availability and clinical deployment, alongside completion of Light AI’s ongoing US pivotal study and any subsequent FDA submission. (Light AI)
Primary Source	Light AI / Health Canada medical device licensing announcement
Relevant Date	14 August 2026

---

Discover how nuaxia can support your next medical education initiative:

• Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector 

• Contact us on: support@nuaxia.com